1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
HUTCHMED (China) Limited

HUTCHMED (China) Limited

HCM.L
HUTCHMED (China) LimitedGB flagLondon Stock Exchange
182.00
GBp
+4.00
- -
1.56BMarket Cap
HUTCHMED (China) Limited
HCM.L
(London Stock Exchange)

Recent

price

182.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.26
0.32
0.04
0.09
0.17
0.33
0.36
0.39
0.32
0.31
0.33
0.45
0.5
0.99
0.74
0.64
Revenue per Share
-0.01
- -
0.01
0.01
-0.01
0.01
0.02
-0.04
-0.11
-0.16
-0.18
-0.25
-0.43
0.12
0.04
0.53
Basic EPS, GAAP
-0.06
- -
-0.02
- -
0.01
-0.02
-0.02
-0.02
-0.06
-0.13
-0.12
-0.28
-0.36
0.22
-0.02
-0.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.08
-0.08
-0.07
-0.04
-0.09
-0.06
-0.03
-0.07
-0.18
-0.34
-0.49
-0.66
-1.04
-0.92
-0.87
-0.34
Book Value per Share
0.1
0.1
0.16
0.2
0.18
0.18
0.34
0.78
0.62
0.46
0.74
1.31
0.75
0.87
0.9
1.45
Tangible Book Value per Share
515
517
519
521
526
547
597
617
664
666
698
793
847
850
855
858
Basic Weighted Avg Shares
135
165
22
46
87
178
216
241
214
205
228
356
426
838
630
549
Sales/Revenue/Turnover
-1.93
4
-77.95
-2.28
-20.91
-5.48
-21.61
-22.1
-43.27
-71.45
-86.27
-92.1
-95.27
2.57
-6.44
-6.51
Operating Margin (%)
5
5
2
1
1
2
2
3
4
5
6
7
9
8
12
13
Depreciation Expense
-7
1
4
6
-7
8
12
-27
-75
-106
-126
-195
-361
101
38
457
Net Income, GAAP
- -
50.48
9.4
10.43
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.73
- -
12.76
Effective Tax Rate (%)
-5.1
0.43
16.27
12.87
-8.37
4.49
5.41
-11.08
-34.94
-51.75
-55.15
-54.66
-84.62
12.03
5.99
83.3
Profit Margin (%)
40
52
9
-11
15
8
72
328
285
204
372
900
486
694
690
1,252
Working Capital
- -
- -
27
- -
27
27
27
- -
27
30
33
7
23
51
64
70
LT Debt
69
77
82
105
98
102
204
485
412
313
519
1,040
637
743
772
1,251
Total Equity
- -
3.22
-13.83
-0.68
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.65
- -
-2.81
Return on Invested Capital (%)
- -
0.05
72.59
20.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
-13.34
- -
-111.25
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.82%
28.85%
62.11%
Free Cash Flow
65.28%
68.03%
409.32%
Net Income, GAAP
101.86%
212.15%
1,111.03%
Sales/Revenue/Turnover
16.33%
26.94%
-12.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
838
2024
- -
- -
- -
- -
630
2025
- -
- -
- -
- -
549

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.12
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.53

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Vaishali Pharma Limited (VAISHALI.NS)
FUREN Group Pharmaceutical Co., Ltd. (600781.SS)
Blueberries Medical Corp. (BBM.CN)
Zhejiang AngLiKang Pharmaceutical CO.,LTD. (002940.SZ)
Entourage Health Corp. (ETRGF)
LFTD Partners Inc. (LIFD)
Business
HUTCHMED (China) Limited (HCM.L) discovers, develops, and commercializes targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company offers Fruquintinib (Elunate/Fruzaqla), a selective oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3 approved for metastatic colorectal cancer; Savolitinib (Orpathys), a selective oral inhibitor of c-Met receptor tyrosine kinase for non-small cell lung cancer (NSCLC) and other solid tumors; Surufatinib (Sulanda), an oral inhibitor of VEGFR, FGFR and CSF-1R for neuroendocrine tumors; and Tazemetostat, an oral inhibitor of EZH2 for relapsed or refractory follicular lymphoma. Additional pipeline candidates include AMD3100 for stem cell mobilization in multiple myeloma and lymphoma; Sovleplenib for immune thrombocytopenia; and several early-stage assets such as HMPL-306, HMPL-760, HMPL-813, and HMPL-653 targeting various oncology and immunology indications. HUTCHMED operates primarily in oncology and immunology segments, serving patients and healthcare providers through partnerships with global pharmaceutical companies; its geographic footprint spans China, the United States, Europe, and other international markets. Founded in 2000 and headquartered in Hong Kong and Shanghai, China, the company maintains subsidiaries including Hutchison MediPharma Limited and collaborates with partners such as Takeda, Eli Lilly, and AstraZeneca for global development and commercialization. In recent developments, HUTCHMED completed the acquisition of Inmagene Biopharmaceuticals in 2024, expanding its immunology portfolio with candidates like IMGN632; announced positive topline results from the Phase III SANET-ep trial for Surufatinib in neuroendocrine tumors in China during 2024; and secured FDA approval for Fruzaqla (fruquintinib) in the United States in November 2023, marking its first product launch outside China. The company also reported Phase II data for savolitinib in MET-driven NSCLC and initiated multiple global trials, including for tazemetostat following its 2024 acquisition from Epizyme. These advancements reflect HUTCHMED's strategic shift toward global expansion and late-stage pipeline maturation, bolstered by ongoing funding and partnerships.